Hyperion Therapeutics has begun enrolling patients in its THRIVE study, a long-term registry of patients with urea cycle disorders (UCDs) which will capture clinical outcomes and comparative effectiveness data. Hyperion received FDA approval for Ravicti, an oral medication for the long-term management of high blood levels of ammonia, in February 2013. The THRIVE study is a multi-center, prospective, non-interventional study designed to collect data in as many as 500 UCD patients as part of thei...